Acorda Therapeutics Chief Executive Officer Ron Cohen Elected Chairman of BIO Emerging Companies Section

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President and CEO, has been elected chairman of the Biotechnology Industry Organization (BIO) Emerging Companies Section. The Emerging Companies Section serves the needs of small and medium size BIO member companies, most of whom do not yet have major products approved and on the market. Members of the group examine issues affecting smaller companies and construct programs to enhance their development. Dr. Cohen previously served as the section’s vice chairman.

"Small and emerging biotech companies often times are advancing the most cutting edge technologies, and can benefit tremendously from programs and access to experienced business leaders to help them reach their potential,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. "When I founded Acorda, the guidance I received from established industry leaders was invaluable in helping me build the company. I’m pleased to now chair a group dedicated to providing that same type of support to small companies that are developing the next generation of biotechnology advances.”

Dr. Cohen founded Acorda Therapeutics in 1995 as a private company dedicated to developing novel medications for people with neurological diseases. Today, Acorda is a publicly traded company with two marketed products, including the recently FDA-approved AMPRYA™ (dalfampridine) Extended Release Tablets, 10.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. The Company's marketed products include AMPYRA™ (dalfampridine), a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS); this was demonstrated by an improvement in walking speed; and ZANAFLEX CAPSULES^® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules, the risk of unfavorable results from future studies of Ampyra, the occurrence of adverse safety events with our products, delays in obtaining or failure to obtain regulatory approval of Ampyra outside of the United States and our dependence on our collaboration partner Biogen Idec in connection therewith, competition, failure to protect Acorda Therapeutics’ intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from our preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.